Europe PMC plus
Manuscript Submission Information

**Journal name:** International clinical psychopharmacology

**Manuscript #:** 73031

**Manuscript Title:** Placebo Response in Trichotillomania

**Principal Investigator:**

**Submitter:** Lippincott Williams Wilkins (editorialsolutions@lww.com)

**Manuscript Files**

<table>
<thead>
<tr>
<th>Type</th>
<th>Fig/Table #</th>
<th>Filename</th>
<th>Size</th>
<th>Uploaded</th>
</tr>
</thead>
<tbody>
<tr>
<td>manuscript</td>
<td>Renamed MS</td>
<td>YIC_ICP2703_manuscript.docx</td>
<td>48747</td>
<td>2017-06-02 13:46:05</td>
</tr>
<tr>
<td>manuscript</td>
<td>Revised Manuscript Title page Abstract Keywords Text references legends acknowledgements</td>
<td>revised-placebo-TTM-5-14-17 with edit.docx</td>
<td>49354</td>
<td>2017-06-02 13:46:05</td>
</tr>
</tbody>
</table>

This PDF receipt will only be used as the basis for generating Europe PubMed Central (Europe PMC) documents. Europe PMC documents will be made available for review after conversion (approx. 2-3 weeks time). Any corrections that need to be made will be done at that time. No materials will be released to Europe PMC without the approval of an author. Only the Europe PMC documents will appear on Europe PMC -- this PDF Receipt will not appear on Europe PMC.
Placebo Response in Trichotillomania

Jon E. Grant, a Samuel R. Chamberlain, b Sarah A. Redden, a
Brian L. Odlaug, c,d Michael van Ameringen, e
Darin D. Dougherty, f Nancy J. Keuthen, f Suck Won Kim g

aDepartment of Psychiatry & Behavioral Neuroscience, University of Chicago,
Pritzker School of Medicine, Chicago, IL, USA
bDepartment of Psychiatry, University of Cambridge, UK; & Cambridge and Peterborough NHS Foundation Trust, UK
cFaculty of Health & Medical Sciences, School of Public Health, University of Copenhagen,
Denmark
dH. Lundbeck A/S, Valby, Denmark
eDepartment of Psychiatry and Behavioural Neurosciences,
McMaster University, Hamilton, Ontario, Canada.
fDepartment of Psychiatry, Massachusetts General Hospital/Harvard Medical School
Boston, MA, USA
gDepartment of Psychiatry, University of Minnesota,
Minneapolis, MN USA

Address correspondence to:
Jon E. Grant, J.D., M.D., M.P.H.
Department of Psychiatry & Behavioral Neuroscience
Conflicts of Interest and Source Funding: There was no funding for this study. Dr. Grant has received research grant support from TLC Foundation for BFRBs, NIDA, NIAAA, National Center for Responsible Gaming, Brainsway, Psyadon and Takeda Pharmaceuticals. He is on the scientific advisory board of the TLC Foundation for BFRBs. He receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies and has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. Dr. Chamberlain consults for Cambridge Cognition and Shire. Dr. Chamberlain’s involvement in this project was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z). Dr. Odlaug has received research funding from the TLC Foundation for BFRBs and receives royalties from Oxford University Press. He has consulted for and is currently employed by H. Lundbeck A/S. H. Lundbeck A/S had no part in any of the studies mentioned in this paper and did not contribute to this paper in any form. Dr Keuthen has received research support from the TLC Foundation for BFRBs and Forest Laboratories. She receives royalties from New Harbinger Inc. She is on the scientific advisory boards of the TLC Foundation for BFRBs and the International OCD Foundation.

Running title: Trichotillomania and placebo
Abstract

Background: Trichotillomania is a functionally impairing, often overlooked disorder with no FDA-approved medications indicated for its treatment. The ability of clinical trials to detect beneficial effects of pharmacologic treatment in trichotillomania has been hampered by the high placebo response rate. Very little is known about baseline demographic and clinical characteristics that may be predictive of placebo response in such patients.

Methods: 104 participants assigned to placebo were pooled from five double-blind trials conducted at three sites in the United States and Canada. Participants were classified as placebo responders or non-responders based on a cut-off of 35% reduction in symptom severity on the Massachusetts General Hospital Hair Pulling Scale (MGH-HPS). Baseline group differences were characterized using t-tests and equivalent non-parametric tests as appropriate.

Results: Thirty-one percent of individuals assigned to placebo treatment showed a significant clinical response to placebo. Placebo responders (n=32) and non-responders (n=72) did not differ significantly on any demographic or clinical variable.

Discussion: Predictors of placebo response for trichotillomania remain elusive and do not appear similar to those reported for other mental health disorders.
Introduction

Trichotillomania (TTM) is a potentially disabling, under-recognized condition in which individuals repeatedly pull out their hair, leading to hair loss. Psychosocial problems are common among individuals with TTM and may include significantly reduced quality of life, lowered self-esteem, and impaired social functioning (Diefenbach et al., 2005; Houghton et al., 2016; Grant and Chamberlain, 2016). Although trichotillomania has been described for almost two centuries, it remains poorly understood with limited data regarding pathophysiology and treatment (Christenson & Mansueto, 1999; Chamberlain et al., 2009; Grant and Chamberlain, 2016).

Most of the double-blind, placebo-controlled pharmacological studies of TTM have failed to separate symptomatic changes significantly from placebo. Interestingly, our clinical experience suggests that in many cases this lack of effectiveness seems less to do with the medication failing to produce results and more to do with the high placebo response rates. For example, in a double-blind study of inositol, 37% of the placebo group (using a last observation carried forward approach; LOCF) responded (Leppink et al., 2016). Understanding the complexity of the placebo response in these disorders is challenging due to the limited sizes of the research samples (e.g., sample sizes of <25 taking placebo in any single study). The present study seeks to overcome this limitation by using a relatively large data set which combines participants from five double-blind, placebo controlled pharmacological trials in TTM conducted in the United States and Canada (Dougherty et al., 2006; Grant et al., 2009; Van Ameringen et al., 2010; Grant et al., 2014; Leppink et al., 2016).

Understanding the factors associated with a placebo response in TTM may allow for a
more efficient examination of potentially beneficial pharmacological treatments for this disabling disorder. Here, we pooled data from studies in which all participants met diagnostic criteria for TTM, took placebo pills, and were seen regularly by a medical professional. Many factors have been suggested to contribute to high placebo response rates clinical trials in mental health. In the case of major depressive disorder, interpersonal interactions, the strength of the therapeutic alliance with research personnel (Leuchter et al., 2014), or lesser levels of depression severity (Khan et al., 2002; Khan et al., 2005) may result in a placebo response. Data from trials of bipolar depression suggest that baseline illness severity and trial duration predict placebo response (Neirenberg et al., 2015). The case of obsessive compulsive disorder, however, has yielded no clear clinical variables associated with the placebo response (Mataix-Cols, et al., 1999). Based on the (admittedly limited) extant mental health literature and our clinical experience, we hypothesized that the placebo effect in TTM would be associated with milder illness severity at baseline.

Methods

Subjects

Data from participants in TTM treatment studies at the University of Chicago, University of Minnesota, McMaster University, and Massachusetts General Hospital (MGH)/Harvard Medical School who were assigned to placebo during the clinical trial were included in this study (one exception was the sertraline trial which had a 2-week single-blind placebo phase prior to treatment assignment in the double-blind portion of the study and only 2 were randomized to placebo treatment in this study arm). All participants had a primary diagnosis of TTM based on
expert clinical assessment. As is customary in TTM research, prior to May 2013, the diagnosis was based on DSM-IV criteria with or without the endorsement of increasing and decreasing tension associated with pulling (criteria B and C). After the release of the DSM-5 in May 2013, all subjects met the DSM-5 criteria for TTM. Other inclusion criteria included age 18 or older, the ability to be interviewed in person, and able to provide written informed consent. Participants from MGH were excluded if they met criteria for a lifetime diagnosis of psychosis, autism, or mental retardation. Participants at the University of Chicago and the University of Minnesota were excluded if they were pregnant, met lifetime criteria for bipolar disorder or a psychotic disorder, or had an organic mental disorder. Participants taking any psychotropic medications were included as long as the dose of medication had been stable for at least three months prior to study entry. Participants taking part at McMaster University were excluded if they had comorbid primary mental disorders; were less than moderately ill at baseline; had received olanzapine without success in the past; had comorbid OCD, depression, substance use disorder; or had a lifetime history of schizophrenia, bipolar disorder, dementia, or other neurologic disorders.

All study procedures were carried out in accordance with the latest version of the Declaration of Helsinki. Study approvals were received from the Institutional Review Boards of all relevant institutions prior to study initiation. Detailed methodologies of the various clinical trials have been previously published (Dougherty et al., 2006; Grant et al., 2009; Van Ameringen et al., 2010; Grant et al., 2014; Leppink et al., 2016). Data were de-identified according to the Safe Harbor method for de-identification prior to data sharing (§164.514(b)) (U.S. Department of Health & Human Services, 2012). After all procedures were explained, all participants provided written informed consent.
All participants in the trials completed a full psychiatric assessment using the Structured Clinical Interview for DSM-IV (SCID-I) (First et al. 1995). Subjects also completed general demographic questionnaires, and self-report and clinician-administered severity measures. In addition, each subject underwent a semi-structured interview to examine psychiatric disorders in first-degree relatives (except for the sertraline study). No relatives were interviewed directly.

Assessments

The *Massachusetts General Hospital Hair Pulling Scale (MGH-HPS)* (Keuthen et al., 1995) was used to assess severity of TTM symptoms. The MGH-HPS is a valid and reliable seven-item, self-report scale that rates urges to pull hair, actual amount of pulling, perceived control over behavior, and distress associated with hair pulling over the preceding seven days. Analysis of the MGH-HPS has demonstrated two separate factors with acceptable reliability for both: “severity” and “resistance and control” (Keuthen et al., 2007).

Psychosocial functioning was assessed using the *Sheehan Disability Scale (SDS)* (Sheehan, 1983): The SDS is a valid and reliable, three-item, self-report scale that assesses psychosocial functioning in work, social or leisure activities, and home/family life. Scores on the scale range from 0 to 30 with higher scores indicating better perceived psychosocial functioning.

Depression and anxiety symptoms over the past month were assessed using clinician-administered *Hamilton Depression Rating Scale* (HAM-D; Hamilton, 1960) and *Hamilton Anxiety Rating Scale* (HAM-A; Hamilton, 1959), respectively. Scores on these two measures were not a basis for inclusion/exclusion.
Data Analysis

Baseline characteristics of the placebo participants pooled from all of the studies were presented in terms of means and standard deviations for continuous variables and frequencies and percentages for categorical variables.

Patients were grouped as placebo responders (>35% reduction in MGH-HPS total scores from baseline to end-point) or non-responders. The two groups were compared on pertinent demographic and clinical measures using independent sample t-tests or equivalent non-parametric tests as indicated in the text. This being an exploratory study, statistical significance was defined as p<0.05 uncorrected, one-tailed.

As a secondary analysis, we also pooled all data from the same studies from active treatment responders, and compared these data to those of placebo responders.

Results

Data from 104 participants with primary TTM (N=91 [87.5%] female, mean age 32.6 ± 11.0 years) who were assigned placebo were included in the analysis. In the pooled analysis, 31.4% of participants assigned to placebo improved at least 35% on the MGH-HPS during placebo treatment.

In terms of the individual studies, the sample sizes for those receiving placebo, and N [%] of subjects responding to placebo, were as follows: Inositol N=19, 7 [36.8%] were placebo responders; N-acetylcysteine (NAC) N=25, 6 [24.0%] were placebo responders; Naltrexone N=30, 9 [30.0%] were placebo responders; Olanzapine N=12, 3 [25.0%] were placebo responders; Sertraline N=18, 7 [39.9%] were placebo responders. The studies did not differ
significantly on placebo response rate (Likelihood Ratio = 1.619, df=4, p=0.805).

Clinical variables of responders and non-responders are presented in Table 1, where it can be seen that the groups did not differ from each other in terms of demographic variables or clinical characteristics. Clinical variables of placebo responders are compared to reference data for active treatment responders in Table 2. Active treatment responders completed significantly more study weeks than placebo responders, and had marginally higher rate of OCD (although OCD was uncommon in both groups).

Table 1. Clinical Variables of Participants with Trichotillomania Who Did and Did Not Respond to Placebo

<table>
<thead>
<tr>
<th>Variables</th>
<th>Those Who Responded to Placebo (n=32)</th>
<th>Those Who Did Not Respond to Placebo (n=72)</th>
<th>Statistical Test</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>30.4 (10.9)</td>
<td>33.5 (11.0)</td>
<td>t=1.314, df=1,102</td>
<td>0.192</td>
</tr>
<tr>
<td>Gender, female, N [%]</td>
<td>28 [87.5%]</td>
<td>63 [87.5%]</td>
<td>LR=0.772, df=2</td>
<td>0.680</td>
</tr>
<tr>
<td>Education level</td>
<td>3.6 (1.2)</td>
<td>3.6 (1.3)</td>
<td>t=0.062, df=1,68</td>
<td>0.951</td>
</tr>
<tr>
<td>Race, white Caucasian, N [%]</td>
<td>20 [98.0%]</td>
<td>48 [98.0%]</td>
<td>LR=0.691, df=1</td>
<td>0.406</td>
</tr>
<tr>
<td>Frequency of hair pulling (mean number of minutes per day during the week prior to study entry)</td>
<td>66.6 (38.6)</td>
<td>87.7 (67.1)</td>
<td>t=1.379, df=1,72</td>
<td>0.172</td>
</tr>
<tr>
<td>Clinical Variable</td>
<td>MGH-HPS Total Score at Baseline</td>
<td>Weeks of Study Completed</td>
<td>Previous Treatment for Trichotillomania, Yes, N[%]</td>
<td>First Degree Relative with Grooming Disorder, “Yes” N[%]</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>---------------------------------</td>
<td>--------------------------</td>
<td>---------------------------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>17.4 (3.4)</td>
<td>8.5 (3.6)</td>
<td>14 [63.6%]</td>
<td>3 [13.6%]</td>
</tr>
<tr>
<td></td>
<td>18.2 (4.6)</td>
<td>8.3 (3.9)</td>
<td>29 [56.9%]</td>
<td>6 [11.5%]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LR = 0.294, df=1</td>
<td>LR = 0.063, df=1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All values are mean (±SD) for continuous variables and N [%] for categorical variables. Abbreviations: LR = likelihood ratio test. @ = one individual in the non-placebo responders group identified as intersex.

Table 2. Clinical Variables of Participants with Trichotillomania Who Were Placebo Responders Compared to Active Treatment Responders
<table>
<thead>
<tr>
<th>Variables</th>
<th>Those Who Responded to Placebo (n=32)</th>
<th>Those Who Responded to Active Treatment (n=52)</th>
<th>Statistical Test</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>30.4 (10.9)</td>
<td>32.6 (11.1)</td>
<td>t=0.865, df=1,82</td>
<td>0.390</td>
</tr>
<tr>
<td>Gender, female, N [%]</td>
<td>28 [87.5%]</td>
<td>44 [84.6%]</td>
<td>LR=0.992, df=2</td>
<td>0.601</td>
</tr>
<tr>
<td>Education level</td>
<td>3.6 (1.2)</td>
<td>3.8 (1.0)</td>
<td>t=0.638, df=1,55</td>
<td>0.527</td>
</tr>
<tr>
<td>Race, white Caucasian, N [%]</td>
<td>20 [98.0%]</td>
<td>33 [94.3%]</td>
<td>LR=1.851, df=1</td>
<td>0.396</td>
</tr>
<tr>
<td>Frequency of hair pulling (mean number of minutes per day during the week prior to study entry)</td>
<td>66.6 (38.6)</td>
<td></td>
<td>t=1.379, df=72</td>
<td>0.172</td>
</tr>
<tr>
<td>MGH-HPS total score at baseline</td>
<td>17.4 (3.4)</td>
<td>17.9 (4.1)</td>
<td>t=0.619, df=1,82</td>
<td>0.538</td>
</tr>
<tr>
<td>Weeks of study completed</td>
<td>8.5 (3.6)</td>
<td>10.2 (2.2)</td>
<td>t=2.073, df=1,56</td>
<td><strong>0.047</strong></td>
</tr>
<tr>
<td>Previous treatment for trichotillomania, yes, N [%]</td>
<td>14 [63.6%]</td>
<td>20 [55.6%]</td>
<td>LR=0.370, df = 1</td>
<td>0.543</td>
</tr>
<tr>
<td>First degree relative with grooming disorder, “yes” N [%]</td>
<td>3 [13.6%]</td>
<td>6 [16.7%]</td>
<td>LR = 0.097, df=1</td>
<td>0.755</td>
</tr>
<tr>
<td>Sheehan Disability Scale</td>
<td>10.9 (6.7)</td>
<td>11.4 (7.0)</td>
<td>t=1.145, df=1,56</td>
<td>0.258</td>
</tr>
</tbody>
</table>
Discussion

To our knowledge, this is the first study that has examined clinical variables associated with the placebo response in the pharmacological treatment of TTM. Given that the pooled placebo response in these studies was 31%, and that there is as of yet no FDA-approved medication indicated for the treatment of TTM, determining predictors of placebo response is crucial for the timely and cost-effective development of pharmacological interventions. Knowledge of variables associated with placebo response might also be useful for sample enrichment in clinical trials. In addition, a placebo response rate of 31% suggests that larger numbers will be needed in future placebo controlled efficacy studies of TTM than have been previously considered necessary.

Some research suggests that the placebo effect in clinical drug trials generally may
influence as many as 49% of treated patients, that the effect may be related to symptom severity, and that its duration may vary from minutes to years (Breidert & Hofbauer, 2009). Interestingly, the placebo response rate in our sample is much higher than previously found in OCD treatment trials, a disorder with possible biological links to TTM (<20%; Greist et al., 1995; Stein et al., 1995; Pigott & Seay, 1999; Ackerman & Greenland, 2002; Stein et al., 2006;). Whether this difference is reflective of methodological issues or more substantial biological differences between TTM and OCD, however, remains unclear.

This study found no differences between those who did and did not respond to placebo. Contrary to our expectations, baseline symptom severity did not differ between placebo responders and non-responders. The differences between our results and studies of other mental health conditions such as major depressive disorder in which baseline symptom severity was a meaningful predictor of placebo response (Stein et al., 2006; Nierenberg et al., 2015) could reflect the particular characteristics of our subject population or of the disorder itself. Surprisingly, in view of the contribution of placebo response to clinical outcomes in trials, relatively few studies have explored predictors of placebo response, especially so in obsessive-compulsive and related disorders. Our findings of a lack of predictive variables are in broad terms with several previous papers in OCD, which reported no statistically significant predictors (DeVeauGeiss et al., 1990; Mataix-Cols et al., 1999).

Our comparison of baseline characteristics between placebo responders and active treatment responders (data pooled from the same source studies) was similarly negative, except for two findings. Active treatment responders stayed in the trials for a longer period of time and had marginally higher occurrence of OCD than placebo responders. The former result probably
stems from greater treatment benefit participants may experience with at least some of the active treatments reported in the literature, compared to placebo, even if placebo subjects respond somewhat to placebo. The latter result is likely a chance finding as the actual numbers of patients with OCD was low in both groups, and data were generally from randomized trials.

One possible explanation for the high placebo response in TTM studies could be phenotypic variation seen in the disorder. For example, some individuals pull only from their eyebrows or eyelashes. In these cases, it is quite common to pull all of the hair and then report no pulling for several weeks until the hair regrows. This is quite distinct from people who pull from their heads as that variation tends to be more chronic. Of course, a complication is that many people pull from several areas as well. Having said that, future studies may wish to enroll only those who pull from their heads and therefore have a chronic and predictable course so that change in behavior could more reliably be attributed to the intervention and not the lack of hair or need for hair to regrow.

This study suggests that few (if any) typically collected baseline clinical characteristics in TTM distinguish placebo responders from non-responders, but there exist several limitations to the studies included in the pooled analysis. Some studies unrelated to TTM suggest that expectancy (i.e. an individual’s beliefs about whether he or she will improve due to the treatment) may play a large role in a placebo response (Brown, 1994; Linden, 2017). Expectancy was not measured in the studies analyzed here. Although the MGH-HPS scoring has demonstrated strong validity and reliability in previous trials as reflecting a response to medication, the ideal threshold for response remains somewhat in doubt (Houghton et al., 2015). We chose a 35% reduction as being clinically meaningful, but some authors suggest that a 45% reduction may be more optimal.
for TTM (Houghton et al., 2015). In response to this suggestion, we also examined the current measures using a 45% definition in a post-hoc analysis (data not reported), with similar lack of significant results. Some clinical measures were available only for a subset of individuals in the pooled dataset. This study did not examine baseline cognition or brain function. Such types of baseline measures would merit scrutiny in future work. This may in the future be a useful means of distinguishing placebo responders from non-responders before treatment, especially given that the placebo response can be linked with changes in brain functioning in other context (Leuchter et al., 2002). The studies included in the present paper had some restrictions on comorbidity in the protocols which might explain the low rates of comorbid OCD or alcohol use disorder. If the studies had broader inclusion criteria allowing for comorbidity, it is possible that certain co-occurring disorders may have contributed to the placebo response. The duration of treatment by week is reported and thus it would be important to analyze the placebo for each week of the studies. Given the collective data, this was not possible across all studies and should be noted as a limitation. Lastly, although this study represents the largest sample of subjects in treatment trials for TTM, the sample size is still relatively small and thus had only modest power to detect moderate effect size. The current sample size, however, had adequate power (power ~ 0.80) to detect a group difference on a given measure of interest with medium (Cohen’s $D$ at least 0.6) effect size, and it had very high power (power ~ 0.96) to detect a group difference with large effect size (Cohen’s $D$ of 0.8).

Placebo-controlled studies are the gold standard for the examination of pharmacological interventions. Individuals with TTM who respond to placebo appear no different clinically from those who do not respond to placebo, based on the types of measure typically collected in existing
clinical trials. Given the fairly high estimated prevalence of TTM (Christensen et al., 1991; Odlaug & Grant, 2010) and the associated reduced quality of life in those who struggle with this disorder (Houghton et al. 2016; Odlaug et al. 2010; Tung et al., 2014), further exploration of placebo response will be crucial for developing better pharmacological interventions. Of course, it is not possible to discuss meaningfully treatment resistance in TTM since there is no licensed treatment and only a limited evidence base of efficacy for any treatment.
References


Grant JE, Odlaug BL, Kim SW. (2009). N-acetylcysteine, a glutamate modulator, in the treatment
of trichotillomania: a double-blind, placebo-controlled study. *Arch Gen Psychiatry* 66(7):756-63.


Placebo Response in Trichotillomania

Jon E. Grant, a Samuel R. Chamberlain, b Sarah A. Redden, a
Brian L. Odlaug, c,d Michael van Ameringen, e
Darin D. Dougherty, f Nancy J. Keuthen, f Suck Won Kim g

a Department of Psychiatry & Behavioral Neuroscience, University of Chicago,
  Pritzker School of Medicine, Chicago, IL, USA
b Department of Psychiatry, University of Cambridge, UK; & Cambridge and Peterborough NHS
  Foundation Trust, UK
c Faculty of Health & Medical Sciences, School of Public Health, University of Copenhagen,
  Denmark
d H. Lundbeck A/S, Valby, Denmark
e Department of Psychiatry and Behavioural Neurosciences,
  McMaster University, Hamilton, Ontario, Canada.
f Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School
  Boston, MA, USA
g Department of Psychiatry, University of Minnesota,
  Minneapolis, MN USA

Address correspondence to:
Jon E. Grant, J.D., M.D., M.P.H.
Department of Psychiatry & Behavioral Neuroscience
Conflicts of Interest and Source Funding: There was no funding for this study. Dr. Grant has received research grant support from TLC Foundation for BFRBs, NIDA, NIAAA, National Center for Responsible Gaming, Brainsway, Psyadon and Takeda Pharmaceuticals. He is on the scientific advisory board of the TLC Foundation for BFRBs. He receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies and has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. Dr. Chamberlain consults for Cambridge Cognition and Shire. Dr. Chamberlain’s involvement in this project was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z). Dr. Odlaug has received research funding from the TLC Foundation for BFRBs and receives royalties from Oxford University Press. He has consulted for and is currently employed by H. Lundbeck A/S. H. Lundbeck A/S had no part in any of the studies mentioned in this paper and did not contribute to this paper in any form. Dr Keuthen has received research support from the TLC Foundation for BFRBs and Forest Laboratories. She receives royalties from New Harbinger Inc. She is on the scientific advisory boards of the TLC Foundation for BFRBs and the International OCD Foundation.

Running title: Trichotillomania and placebo
Abstract

Background: Trichotillomania is a functionally impairing, often overlooked disorder with no FDA-approved medications indicated for its treatment. The ability of clinical trials to detect beneficial effects of pharmacologic treatment in trichotillomania has been hampered by the high placebo response rate. Very little is known about baseline demographic and clinical characteristics that may be predictive of placebo response in such patients.

Methods: 104 participants assigned to placebo were pooled from five double-blind trials conducted at three sites in the United States and Canada. Participants were classified as placebo responders or non-responders based on a cut-off of 35% reduction in symptom severity on the Massachusetts General Hospital Hair Pulling Scale (MGH-HPS). Baseline group differences were characterized using t-tests and equivalent non-parametric tests as appropriate.

Results: Thirty-one percent of individuals assigned to placebo treatment showed a significant clinical response to placebo. Placebo responders (n=32) and non-responders (n=72) did not differ significantly on any demographic or clinical variable.

Discussion: Predictors of placebo response for trichotillomania remain elusive and do not appear similar to those reported for other mental health disorders.
Introduction

Trichotillomania (TTM) is a potentially disabling, under-recognized condition in which individuals repeatedly pull out their hair, leading to hair loss. Psychosocial problems are common among individuals with TTM and may include significantly reduced quality of life, lowered self-esteem, and impaired social functioning (Diefenbach et al., 2005; Houghton et al., 2016; Grant and Chamberlain, 2016). Although trichotillomania has been described for almost two centuries, it remains poorly understood with limited data regarding pathophysiology and treatment (Christenson & Mansueto, 1999; Chamberlain et al., 2009; Grant and Chamberlain, 2016).

Most of the double-blind, placebo-controlled pharmacological studies of TTM have failed to separate symptomatic changes significantly from placebo. Interestingly, our clinical experience suggests that in many cases this lack of effectiveness seems less to do with the medication failing to produce results and more to do with the high placebo response rates. For example, in a double-blind study of inositol, 37% of the placebo group (using a last observation carried forward approach; LOCF) responded (Leppink et al., 2016). Understanding the complexity of the placebo response in these disorders is challenging due to the limited sizes of the research samples (e.g., sample sizes of <25 taking placebo in any single study). The present study seeks to overcome this limitation by using a relatively large data set which combines participants from five double-blind, placebo controlled pharmacological trials in TTM conducted in the United States and Canada (Dougherty et al., 2006; Grant et al., 2009; Van Ameringen et al., 2010; Grant et al., 2014; Leppink et al., 2016).

Understanding the factors associated with a placebo response in TTM may allow for a
more efficient examination of potentially beneficial pharmacological treatments for this disabling disorder. Here, we pooled data from studies in which all participants met diagnostic criteria for TTM, took placebo pills, and were seen regularly by a medical professional. Many factors have been suggested to contribute to high placebo response rates clinical trials in mental health. In the case of major depressive disorder, interpersonal interactions, the strength of the therapeutic alliance with research personnel (Leuchter et al., 2014), or lesser levels of depression severity (Khan et al., 2002; Khan et al., 2005) may result in a placebo response. Data from trials of bipolar depression suggest that baseline illness severity and trial duration predict placebo response (Neirenberg et al., 2015). The case of obsessive compulsive disorder, however, has yielded no clear clinical variables associated with the placebo response (Mataix-Cols, et al., 1999). Based on the (admittedly limited) extant mental health literature and our clinical experience, we hypothesized that the placebo effect in TTM would be associated with milder illness severity at baseline.

**Methods**

**Subjects**

Data from participants in TTM treatment studies at the University of Chicago, University of Minnesota, McMaster University, and Massachusetts General Hospital (MGH)/Harvard Medical School who were assigned to placebo during the clinical trial were included in this study (one exception was the sertraline trial which had a 2-week single-blind placebo phase prior to treatment assignment in the double-blind portion of the study and only 2 were randomized to placebo treatment in this study arm). All participants had a primary diagnosis of TTM based on
expert clinical assessment. As is customary in TTM research, prior to May 2013, the diagnosis was based on DSM-IV criteria with or without the endorsement of increasing and decreasing tension associated with pulling (criteria B and C). After the release of the DSM-5 in May 2013, all subjects met the DSM-5 criteria for TTM. Other inclusion criteria included age 18 or older, the ability to be interviewed in person, and able to provide written informed consent. Participants from MGH were excluded if they met criteria for a lifetime diagnosis of psychosis, autism, or mental retardation. Participants at the University of Chicago and the University of Minnesota were excluded if they were pregnant, met lifetime criteria for bipolar disorder or a psychotic disorder, or had an organic mental disorder. Participants taking any psychotropic medications were included as long as the dose of medication had been stable for at least three months prior to study entry. Participants taking part at McMaster University were excluded if they had comorbid primary mental disorders; were less than moderately ill at baseline; had received olanzapine without success in the past; had comorbid OCD, depression, substance use disorder; or had a lifetime history of schizophrenia, bipolar disorder, dementia, or other neurologic disorders.

All study procedures were carried out in accordance with the latest version of the Declaration of Helsinki. Study approvals were received from the Institutional Review Boards of all relevant institutions prior to study initiation. Detailed methodologies of the various clinical trials have been previously published (Dougherty et al., 2006; Grant et al., 2009; Van Ameringen et al., 2010; Grant et al., 2014; Leppink et al., 2016). Data were de-identified according to the Safe Harbor method for de-identification prior to data sharing (§164.514(b)) (U.S. Department of Health & Human Services, 2012). After all procedures were explained, all participants provided written informed consent.
All participants in the trials completed a full psychiatric assessment using the Structured Clinical Interview for DSM-IV (SCID-I) (First et al. 1995). Subjects also completed general demographic questionnaires, and self-report and clinician-administered severity measures. In addition, each subject underwent a semi-structured interview to examine psychiatric disorders in first-degree relatives (except for the sertraline study). No relatives were interviewed directly.

Assessments

The Massachusetts General Hospital Hair Pulling Scale (MGH-HPS) (Keuthen et al., 1995) was used to assess severity of TTM symptoms. The MGH-HPS is a valid and reliable seven-item, self-report scale that rates urges to pull hair, actual amount of pulling, perceived control over behavior, and distress associated with hair pulling over the preceding seven days. Analysis of the MGH-HPS has demonstrated two separate factors with acceptable reliability for both: “severity” and “resistance and control” (Keuthen et al., 2007).

Psychosocial functioning was assessed using the Sheehan Disability Scale (SDS) (Sheehan, 1983): The SDS is a valid and reliable, three-item, self-report scale that assesses psychosocial functioning in work, social or leisure activities, and home/family life. Scores on the scale range from 0 to 30 with higher scores indicating better perceived psychosocial functioning.

Depression and anxiety symptoms over the past month were assessed using clinician-administered Hamilton Depression Rating Scale (HAM-D; Hamilton, 1960) and Hamilton Anxiety Rating Scale (HAM-A; Hamilton, 1959), respectively. Scores on these two measures were not a basis for inclusion/exclusion.
**Data Analysis**

Baseline characteristics of the placebo participants pooled from all of the studies were presented in terms of means and standard deviations for continuous variables and frequencies and percentages for categorical variables.

Patients were grouped as placebo responders (>35% reduction in MGH-HPS total scores from baseline to end-point) or non-responders. The two groups were compared on pertinent demographic and clinical measures using independent sample t-tests or equivalent non-parametric tests as indicated in the text. This being an exploratory study, statistical significance was defined as p<0.05 uncorrected, one-tailed.

As a secondary analysis, we also pooled all data from the same studies from active treatment responders, and compared these data to those of placebo responders.

**Results**

Data from 104 participants with primary TTM (N=91 [87.5%] female, mean age 32.6 ± 11.0 years) who were assigned placebo were included in the analysis. In the pooled analysis, 31.4% of participants assigned to placebo improved at least 35% on the MGH-HPS during placebo treatment.

In terms of the individual studies, the sample sizes for those receiving placebo, and N [%] of subjects responding to placebo, were as follows: Inositol N=19, 7 [36.8%] were placebo responders; N-acetylcysteine (NAC) N=25, 6 [24.0%] were placebo responders; Naltrexone N=30, 9 [30.0%] were placebo responders; Olanzapine N=12, 3 [25.0%] were placebo responders; Sertraline N=18, 7 [39.9%] were placebo responders. The studies did not differ
significantly on placebo response rate (Likelihood Ratio = 1.619, df=4, p=0.805).

Clinical variables of responders and non-responders are presented in Table 1, where it can be seen that the groups did not differ from each other in terms of demographic variables or clinical characteristics. Clinical variables of placebo responders are compared to reference data for active treatment responders in Table 2. Active treatment responders completed significantly more study weeks than placebo responders, and had marginally higher rate of OCD (although OCD was uncommon in both groups).

Table 1. Clinical Variables of Participants with Trichotillomania Who Did and Did Not Respond to Placebo

<table>
<thead>
<tr>
<th>Variables</th>
<th>Those Who Responded to Placebo (n=32)</th>
<th>Those Who Did Not Respond to Placebo (n=72)</th>
<th>Statistical Test</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, years</strong></td>
<td>30.4 (10.9)</td>
<td>33.5 (11.0)</td>
<td>t=1.314, df=1,102</td>
<td>0.192</td>
</tr>
<tr>
<td><strong>Gender, female, N [%]</strong></td>
<td>28 [87.5%]</td>
<td>63 [87.5%]</td>
<td>LR=0.772, df=2 @</td>
<td>0.680</td>
</tr>
<tr>
<td><strong>Education level</strong></td>
<td>3.6 (1.2)</td>
<td>3.6 (1.3)</td>
<td>t=0.062, df=1,68</td>
<td>0.951</td>
</tr>
<tr>
<td><strong>Race, white Caucasian, N [%]</strong></td>
<td>20 [98.0%]</td>
<td>48 [98.0%]</td>
<td>LR=0.691, df=1</td>
<td>0.406</td>
</tr>
<tr>
<td><strong>Frequency of hair pulling (mean number of minutes per day during the week prior to study entry)</strong></td>
<td>66.6 (38.6)</td>
<td>87.7 (67.1)</td>
<td>t=1.379, df=1,72</td>
<td>0.172</td>
</tr>
<tr>
<td>Variable</td>
<td>Placebo Mean (±SD)</td>
<td>Active Treatment Mean (±SD)</td>
<td>t-value</td>
<td>df</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------------</td>
<td>----------------------------</td>
<td>---------</td>
<td>-----</td>
</tr>
<tr>
<td>MGH-HPS total score at baseline</td>
<td>17.4 (3.4)</td>
<td>18.2 (4.6)</td>
<td>0.881</td>
<td>1,102</td>
</tr>
<tr>
<td>Weeks of study completed</td>
<td>8.5 (3.6)</td>
<td>8.3 (3.9)</td>
<td>-0.193</td>
<td>1,72</td>
</tr>
<tr>
<td>Previous treatment for trichotillomania, yes, N[%]</td>
<td>14 [63.6%]</td>
<td>29 [56.9%]</td>
<td>0.294</td>
<td>1</td>
</tr>
<tr>
<td>First degree relative with grooming disorder, “yes” N[%]</td>
<td>3 [13.6%]</td>
<td>6 [11.5%]</td>
<td>0.063</td>
<td>1</td>
</tr>
<tr>
<td>Sheehan Disability Scale</td>
<td>10.9 (6.7)</td>
<td>9.3 (6.3)</td>
<td>0.928</td>
<td>1,102</td>
</tr>
<tr>
<td>HAM-A</td>
<td>4.2 (3.4)</td>
<td>4.7 (3.9)</td>
<td>0.489</td>
<td>1,72</td>
</tr>
<tr>
<td>HAM-D</td>
<td>5.6 (5.9)</td>
<td>6.6 (6.9)</td>
<td>0.633</td>
<td>1,102</td>
</tr>
<tr>
<td>Lifetime Psychiatric History</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mood Disorder</td>
<td>14 [63.6%]</td>
<td>19 [36.5%]</td>
<td>0.0</td>
<td>1</td>
</tr>
<tr>
<td>Anxiety Disorder</td>
<td>5 [22.7%]</td>
<td>9 [17.3%]</td>
<td>0.288</td>
<td>1</td>
</tr>
<tr>
<td>Alcohol Use Disorder</td>
<td>1 [4.5%]</td>
<td>3 [5.8%]</td>
<td>0.047</td>
<td>1</td>
</tr>
<tr>
<td>OCD</td>
<td>0 [0%]</td>
<td>2 [3.8%]</td>
<td>1.435</td>
<td>1</td>
</tr>
<tr>
<td>ADHD</td>
<td>1 [4.5%]</td>
<td>9 [17.3%]</td>
<td>2.561</td>
<td>1</td>
</tr>
</tbody>
</table>

All values are mean (±SD) for continuous variables and N [%] for categorical variables. Abbreviations: LR = likelihood ratio test. @ = one individual in the non-placebo responders group identified as intersex.

Table 2. Clinical Variables of Participants with Trichotillomania Who Were Placebo Responders Compared to Active Treatment Responders
<table>
<thead>
<tr>
<th>Variables</th>
<th>Those Who Responded to Placebo (n=32)</th>
<th>Those Who Responded to Active Treatment (n=52)</th>
<th>Statistical Test</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>30.4 (10.9)</td>
<td>32.6 (11.1)</td>
<td>t=0.865, df=1,82</td>
<td>0.390</td>
</tr>
<tr>
<td>Gender, female, N [%]</td>
<td>28 [87.5%]</td>
<td>44 [84.6%]</td>
<td>LR=0.992, df=2 @</td>
<td>0.601</td>
</tr>
<tr>
<td>Education level</td>
<td>3.6 (1.2)</td>
<td>3.8 (1.0)</td>
<td>t=0.638, df=1,55</td>
<td>0.527</td>
</tr>
<tr>
<td>Race, white Caucasian, N [%]</td>
<td>20 [98.0%]</td>
<td>33 [94.3%]</td>
<td>LR=1.851, df=1</td>
<td>0.396</td>
</tr>
<tr>
<td>Frequency of hair pulling</td>
<td>66.6 (38.6)</td>
<td></td>
<td>t=1.379, df=72</td>
<td>0.172</td>
</tr>
<tr>
<td>Race, white Caucasian, N [%]</td>
<td>20 [98.0%]</td>
<td>33 [94.3%]</td>
<td>LR=1.851, df=1</td>
<td>0.396</td>
</tr>
<tr>
<td>Frequency of hair pulling</td>
<td>66.6 (38.6)</td>
<td></td>
<td>t=1.379, df=72</td>
<td>0.172</td>
</tr>
<tr>
<td>Race, white Caucasian, N [%]</td>
<td>20 [98.0%]</td>
<td>33 [94.3%]</td>
<td>LR=1.851, df=1</td>
<td>0.396</td>
</tr>
<tr>
<td>MGH-HPS total score at baseline</td>
<td>17.4 (3.4)</td>
<td>17.9 (4.1)</td>
<td>t=0.619, df=1,82</td>
<td>0.538</td>
</tr>
<tr>
<td>Weeks of study completed</td>
<td>8.5 (3.6)</td>
<td>10.2 (2.2)</td>
<td>t=2.073, df=1,56</td>
<td><strong>0.047</strong></td>
</tr>
<tr>
<td>Previous treatment for trichotillomania, yes, N [%]</td>
<td>14 [63.6%]</td>
<td>20 [55.6%]</td>
<td>LR=0.370, df = 1</td>
<td>0.543</td>
</tr>
<tr>
<td>First degree relative with grooming disorder, “yes” N [%]</td>
<td>3 [13.6%]</td>
<td>6 [16.7%]</td>
<td>LR = 0.097, df=1</td>
<td>0.755</td>
</tr>
<tr>
<td>Sheehan Disability Scale</td>
<td>10.9 (6.7)</td>
<td>11.4 (7.0)</td>
<td>t=1.145, df=1,56</td>
<td>0.258</td>
</tr>
<tr>
<td></td>
<td>HAM-A</td>
<td>HAM-D</td>
<td>t=0.044, df=1.56</td>
<td>0.965</td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
<td>-------</td>
<td>------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Lifetime Psychiatric History</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mood Disorder</td>
<td>14 [63.6%]</td>
<td>16 [44.4%]</td>
<td>LR=0.370, df=1</td>
<td>0.543</td>
</tr>
<tr>
<td>Anxiety Disorder</td>
<td>5 [22.7%]</td>
<td>9 [25.0%]</td>
<td>LR=0.039, df=1</td>
<td>0.844</td>
</tr>
<tr>
<td>Alcohol Use Disorder</td>
<td>1 [4.5%]</td>
<td>0 [0.0%]</td>
<td>LR=1.968, df=1</td>
<td>0.161</td>
</tr>
<tr>
<td>OCD</td>
<td>0 [0%]</td>
<td>4 [11.1%]</td>
<td>LR=3.995, df=1</td>
<td><strong>0.046</strong></td>
</tr>
<tr>
<td>ADHD</td>
<td>1 [4.5%]</td>
<td>5 [13.9%]</td>
<td>LR=1.433, df=1</td>
<td>0.231</td>
</tr>
</tbody>
</table>

All values are mean (±SD) for continuous variables and N [%] for categorical variables. Abbreviations: LR = likelihood ratio test. @ = one individual in the non-placebo responders group identified as intersex.

**Discussion**

To our knowledge, this is the first study that has examined clinical variables associated with the placebo response in the pharmacological treatment of TTM. Given that the pooled placebo response in these studies was 31%, and that there is as of yet no FDA-approved medication indicated for the treatment of TTM, determining predictors of placebo response is crucial for the timely and cost-effective development of pharmacological interventions. Knowledge of variables associated with placebo response might also be useful for sample enrichment in clinical trials. In addition, a placebo response rate of 31% suggests that larger numbers will be needed in future placebo controlled efficacy studies of TTM than have been previously considered necessary.

Some research suggests that the placebo effect in clinical drug trials generally may
influence as many as 49% of treated patients, that the effect may be related to symptom severity, and that its duration may vary from minutes to years (Breidert & Hofbauer, 2009). Interestingly, the placebo response rate in our sample is much higher than previously found in OCD treatment trials, a disorder with possible biological links to TTM (<20%; Greist et al., 1995; Stein et al., 1995; Pigott & Seay, 1999; Ackerman & Greenland, 2002; Stein et al., 2006;). Whether this difference is reflective of methodological issues or more substantial biological differences between TTM and OCD, however, remains unclear.

This study found no differences between those who did and did not respond to placebo. Contrary to our expectations, baseline symptom severity did not differ between placebo responders and non-responders. The differences between our results and studies of other mental health conditions such as major depressive disorder in which baseline symptom severity was a meaningful predictor of placebo response (Stein et al., 2006; Nierenberg et al., 2015) could reflect the particular characteristics of our subject population or of the disorder itself. Surprisingly, in view of the contribution of placebo response to clinical outcomes in trials, relatively few studies have explored predictors of placebo response, especially so in obsessive-compulsive and related disorders. Our findings of a lack of predictive variables are in broad terms with several previous papers in OCD, which reported no statistically significant predictors (DeVeaugh-Geiss et al., 1990; Mataix-Cols et al., 1999).

Our comparison of baseline characteristics between placebo responders and active treatment responders (data pooled from the same source studies) was similarly negative, except for two findings. Active treatment responders stayed in the trials for a longer period of time and had marginally higher occurrence of OCD than placebo responders. The former result probably
stems from greater treatment benefit participants may experience with at least some of the active treatments reported in the literature, compared to placebo, even if placebo subjects respond somewhat to placebo. The latter result is likely a chance finding as the actual numbers of patients with OCD was low in both groups, and data were generally from randomized trials.

One possible explanation for the high placebo response in TTM studies could be phenotypic variation seen in the disorder. For example, some individuals pull only from their eyebrows or eyelashes. In these cases, it is quite common to pull all of the hair and then report no pulling for several weeks until the hair regrows. This is quite distinct from people who pull from their heads as that variation tends to be more chronic. Of course, a complication is that many people pull from several areas as well. Having said that, future studies may wish to enroll only those who pull from their heads and therefore have a chronic and predictable course so that change in behavior could more reliably be attributed to the intervention and not the lack of hair or need for hair to regrow.

This study suggests that few (if any) typically collected baseline clinical characteristics in TTM distinguish placebo responders from non-responders, but there exist several limitations to the studies included in the pooled analysis. Some studies unrelated to TTM suggest that expectancy (i.e. an individual’s beliefs about whether he or she will improve due to the treatment) may play a large role in a placebo response (Brown, 1994; Linden, 2017). Expectancy was not measured in the studies analyzed here. Although the MGH-HPS scoring has demonstrated strong validity and reliability in previous trials as reflecting a response to medication, the ideal threshold for response remains somewhat in doubt (Houghton et al., 2015). We chose a 35% reduction as being clinically meaningful, but some authors suggest that a 45% reduction may be more optimal.
for TTM (Houghton et al., 2015). In response to this suggestion, we also examined the current measures using a 45% definition in a post-hoc analysis (data not reported), with similar lack of significant results. Some clinical measures were available only for a subset of individuals in the pooled dataset. This study did not examine baseline cognition or brain function. Such types of baseline measures would merit scrutiny in future work. This may in the future be a useful means of distinguishing placebo responders from non-responders before treatment, especially given that the placebo response can be linked with changes in brain functioning in other context (Leuchter et al., 2002). The studies included in the present paper had some restrictions on comorbidity in the protocols which might explain the low rates of comorbid OCD or alcohol use disorder. If the studies had broader inclusion criteria allowing for comorbidity, it is possible that certain co-occurring disorders may have contributed to the placebo response. The duration of treatment by week is reported and thus it would be important to analyze the placebo for each week of the studies. Given the collective data, this was not possible across all studies and should be noted as a limitation. Lastly, although this study represents the largest sample of subjects in treatment trials for TTM, the sample size is still relatively small and thus had only modest power to detect moderate effect size. The current sample size, however, had adequate power (power ~ 0.80) to detect a group difference on a given measure of interest with medium (Cohen’s $D$ at least 0.6) effect size, and it had very high power (power ~ 0.96) to detect a group difference with large effect size (Cohen’s $D$ of 0.8).

Placebo-controlled studies are the gold standard for the examination of pharmacological interventions. Individuals with TTM who respond to placebo appear no different clinically from those who do not respond to placebo, based on the types of measure typically collected in existing
clinical trials. Given the fairly high estimated prevalence of TTM (Christensen et al., 1991; Odlaug & Grant, 2010) and the associated reduced quality of life in those who struggle with this disorder (Houghton et al. 2016; Odlaug et al. 2010; Tung et al., 2014), further exploration of placebo response will be crucial for developing better pharmacological interventions. Of course, it is not possible to discuss meaningfully treatment resistance in TTM since there is no licensed treatment and only a limited evidence base of efficacy for any treatment.
References


Grant JE, Odlaug BL, Kim SW. (2009). N-acetylcysteine, a glutamate modulator, in the treatment
of trichotillomania: a double-blind, placebo-controlled study. *Arch Gen Psychiatry* 66(7):756-63.


